← Research library

Safety and Efficacy of Cerebrolysin for Neurorecovery After Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of 14 Randomized Controlled Trials

Review of earlier studies · 2025

What was studied
2025 meta-analysis reporting 14 randomized trials
Main finding
The review reports a neurological-scale benefit, but functional independence and mortality were not significantly improved.

Study data at a glance

Participants or experimental model
2025 meta-analysis reporting 14 randomized trials
Reported results
The review reports a neurological-scale benefit, but functional independence and mortality were not significantly improved.
Study limitations and source details

Study limitations

  • Table 8 calls hemorrhagic transformation statistically significant, contrary to the abstract’s wording; the discrepancy remains in the publication.
  • Tables 2, 5 and 6 list both CARS-1 and the pooled CARS report. CARS denominators also differ between tables (448 versus 240). Cohort independence and extraction need reconciliation.
  • Safety totals differ between the headline sample and Table 8. Numerical pooled effects are withheld rather than treated as verified estimates.

Source details

Full PMC article: study-characteristic and outcome tables 1–8 checked. Primary trial datasets and forest-plot inputs have not been independently reconstructed.

Full-text reporting checks; reconstruction pending

Sources checked

Citation

ReviewFull text available

Patel PN, Mangal D, Patel K. Safety and Efficacy of Cerebrolysin for Neurorecovery After Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of 14 Randomized Controlled Trials Cureus · PMID 41018475

Study source ↗ · DOI 10.7759/cureus.91054 · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards